Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

AIDS vaccine described by Takeda

July 8, 1997

HIV protease inhibitors described by Searle

July 7, 1997

Novel, irreversible HIV protease inhibitor disclosed by LG Chemical

July 2, 1997

Recombinant multiantigen AIDS vaccine enters second phase I trial

July 1, 1997

Three-drug therapy shown effective against AIDS

June 24, 1997

LMW inhibitor of Tat-TAR interaction and HIV replication prepared at Novartis

June 18, 1997

FDA advisory on AIDS drugs

June 17, 1997

Second-generation NNRTI under development by Hoechst/Bayer

June 16, 1997

Paracelsian cancels launch of AndroVir

June 12, 1997

Carbovir not associated with mitochondrial toxicity in intact cells

June 12, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...